The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro
Background: Resistance to platinum-based chemotherapy is a clinical challenge in the treatment of ovarian cancer (OC) and limits survival. Therefore, innovative drugs against platinum-resistance are urgently needed. Our therapeutic concept is based on the conjugation of two chemotherapeutic compound...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
August 14, 2017
|
| In: |
OncoTarget
Year: 2017, Volume: 8, Issue: 44, Pages: 76935-76948 |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.20260 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.18632/oncotarget.20260 Verlag, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652753/ 
|
| Author Notes: | Sarah Schott, Pauline Wimberger, Barbara Klink, Konrad Grützmann, Julian Puppe, Ulrike Sophie Wauer, Daniel Martin Klotz, Evelin Schröck and Jan Dominik Kuhlmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580059589 | ||
| 003 | DE-627 | ||
| 005 | 20230427065641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180815s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.20260 |2 doi | |
| 035 | |a (DE-627)1580059589 | ||
| 035 | |a (DE-576)510059589 | ||
| 035 | |a (DE-599)BSZ510059589 | ||
| 035 | |a (OCoLC)1341016988 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schott, Sarah |d 1981- |e VerfasserIn |0 (DE-588)133730816 |0 (DE-627)552697281 |0 (DE-576)27460678X |4 aut | |
| 245 | 1 | 4 | |a The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro |c Sarah Schott, Pauline Wimberger, Barbara Klink, Konrad Grützmann, Julian Puppe, Ulrike Sophie Wauer, Daniel Martin Klotz, Evelin Schröck and Jan Dominik Kuhlmann |
| 264 | 1 | |c August 14, 2017 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.08.2018 | ||
| 520 | |a Background: Resistance to platinum-based chemotherapy is a clinical challenge in the treatment of ovarian cancer (OC) and limits survival. Therefore, innovative drugs against platinum-resistance are urgently needed. Our therapeutic concept is based on the conjugation of two chemotherapeutic compounds to a monotherapeutic pro-drug, which is taken up by cancer cells and cleaved into active cytostatic metabolites. We explore the activity of the duplex-prodrug 5-FdU-ECyd, covalently linking 2'-deoxy-5-fluorouridine (5-FdU) and 3'-C-ethynylcytidine (ECyd), on platinum-resistant OC cells. Methods: In vitro assays and RNA-Sequencing were applied for characterization of 5-FdU-ECyd treated platinum-sensitive A2780 and isogenic platinum-resistant A2780cis and independent platinum-resistant Skov-3-IP OC cells. Results: Nano molar 5-FdU-ECyd concentrations induced a rapid dose-dependent decline of cell viability in platinum-sensitive and -resistant OC cells. The effect of 5-FdU-ECyd was accompanied by the formation of DNA double strand breaks and apoptosis induction, indicated by a strong increase of pro-apoptotic molecular markers. Moreover, 5-FdU-ECyd efficiently decreased migration of platinum-resistant OC cells and inhibited clonogenic or spheroidal growth. Transcriptome analysis showed early up-regulation of CDKN1A and c-Fos in both, platinum-resistant and -sensitive cells after 5-FdU-ECyd treatment and de-regulation of distinct cellular pathways involved in cell cycle regulation, apoptosis, DNA-damage response and RNA-metabolism. Combined treatment of 5-FdU-ECyd and cisplatin did not show a synergistic cellular response, suggesting the potential use of 5-FdU-ECyd as a monotherapeutic agent. Conclusion: Our data provide novel mechanistic insight into the anti-tumor effect of 5-FdU-ECyd and we hypothesize that this duplex-prodrug could be a promising therapeutic option for OC patients with resistance to platinum-based chemotherapy. | ||
| 773 | 0 | 8 | |i Enthalten in |t OncoTarget |d [Erscheinungsort nicht ermittelbar] : Impact Journals LLC, 2010 |g 8(2017), 44, Seite 76935-76948 |h Online-Ressource |w (DE-627)63035975X |w (DE-600)2560162-3 |w (DE-576)325343764 |x 1949-2553 |7 nnas |a The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:44 |g pages:76935-76948 |g extent:14 |a The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.20260 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652753/ |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180815 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 133730816 |a Schott, Sarah |m 133730816:Schott, Sarah |d 910000 |d 910400 |e 910000PS133730816 |e 910400PS133730816 |k 0/910000/ |k 1/910000/910400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1580059589 |e 3022386389 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"14 S."}],"name":{"displayForm":["Sarah Schott, Pauline Wimberger, Barbara Klink, Konrad Grützmann, Julian Puppe, Ulrike Sophie Wauer, Daniel Martin Klotz, Evelin Schröck and Jan Dominik Kuhlmann"]},"origin":[{"dateIssuedDisp":"August 14, 2017","dateIssuedKey":"2017"}],"relHost":[{"pubHistory":["1.2010,Mai -"],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"[Erscheinungsort nicht ermittelbar]","publisher":"Impact Journals LLC","dateIssuedDisp":"2010-","dateIssuedKey":"2010"}],"recId":"63035975X","title":[{"title_sort":"OncoTarget","title":"OncoTarget","subtitle":"open access impact journal"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitroOncoTarget","note":["Gesehen am 16.08.2018"],"part":{"pages":"76935-76948","volume":"8","extent":"14","year":"2017","text":"8(2017), 44, Seite 76935-76948","issue":"44"},"id":{"issn":["1949-2553"],"zdb":["2560162-3"],"eki":["63035975X"]}}],"recId":"1580059589","title":[{"title_sort":"conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro","title":"The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Sarah","family":"Schott","role":"aut","display":"Schott, Sarah"}],"note":["Gesehen am 15.08.2018"],"id":{"doi":["10.18632/oncotarget.20260"],"eki":["1580059589"]}} | ||
| SRT | |a SCHOTTSARACONJUGATED1420 | ||